Drugs that cure one ailment but eventually cause cancer are generally frowned upon by the public, especially if the drug is curing something as mundane as baldness.
Research in 2003 on finasteride, the active component of Merck's
Instead, two more recent studies being published in the Journal of the National Cancer Institute demonstrate that the drug shrinks the prostate, allowing doctors to find the aggressive tumors that might have otherwise gone unnoticed.
The research wasn't done by Merck, so it's not clear whether Merck would try to increase the labeling indications for its finasteride to include cancer prevention. Merck markets a higher concentration of the drug under the brand name Proscar for the treatment of benign prostatic hyperplasia in men with enlarged prostates. Proscar had sales of $619 million last year; just imagine the potential sales, should the drug gain widened acceptance as a form of cancer prevention.
At the very least, the study should help Propecia compete with Johnson & Johnson's
Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Johnson & Johnson is an Income Investor recommendation. The Fool's disclosure policy smeared Rogaine all over itself just to see what would happen.
More from The Motley Fool
What Happened in the Stock Market Today
On a day stocks bounced up and down, shares of Energizer Holdings rose on acquisition news, and Merck reported positive results in a lung cancer trial.
These 3 Dividend Giants Are Safer Than You Think
Concerns about these stocks and their dividends are overblown.
Why 2017 Was a Year to Forget for Merck & Co. Inc.
Everything looked OK for the drugmaker until Merck delivered an unwelcome October surprise.